Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register Pacific Edge for InfoPages here.
Pacific Edge - Latest News [Page 1]
Cxbladder Detect+ Now Named Cxbladder Triage Plus
Tuesday, 5 November 2024, 2:30 pm | Pacific Edge
Triage Plus supersedes the working brand name of the test, Cxbladder Detect+. Pacific Edge has adopted the new name because it better reflects the clinical positioning of the new test in helping clinicians to triage patients presenting with hematuria2. More >>
Pacific Edge On The Podium At UAA In Bali
Sunday, 15 September 2024, 10:49 pm | Pacific Edge
Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces its medical presence at the UAA Congress to be held in Bali this week (September 5-8), which has attracted a record attendance of more than 2800 urologists. More >>
AUA Journal Of Urology Editorial Supports Cxbladder
Tuesday, 13 August 2024, 9:55 am | Pacific Edge
Pacific Edge welcomes an editorial in the American Urological Association’s Journal of Urology supporting the use of Cxbladder to reduce unnecessary cystoscopies on patients at risk of bladder cancer. More >>
Novitas Confirms Medicare Coverage Review Extension
Monday, 29 July 2024, 9:45 am | Pacific Edge
Pacific Edge notes that Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, has confirmed that it has been granted an extension to finalise or withdraw the Local Coverage Determination (LCD) ‘Genetic ... More >>
FDA Signals Intent To Regulate Lab Developed Tests
Monday, 2 October 2023, 9:52 am | Pacific Edge
Pacific Edge notes the U.S. Food and Drug Administration (FDA) has released for public comment proposed rule changes that seek to have Laboratory Developed Tests (LDTs) such as Cxbladder regulated as medical devices under the US Federal Food, ... More >>
Study Adds Support For Cxbladder Monitor Use In Cancer Surveillance
Monday, 13 March 2023, 10:24 am | Pacific Edge
Pacific Edge today welcomes the release of new research supporting the clinical utility of the company’s genomic biomarker test Cxbladder Monitor in the surveillance for bladder cancer recurrence. The independent study2 is to be published in the prestigious ... More >>
Pacific Edge Rings The Bell On Two Decades As An NZX Listed Company
Thursday, 9 February 2023, 11:40 am | Pacific Edge
Pacific Edge today rang the bell on two decades of its shares trading on the NZX Main Board. At a ceremony at NZX’s offices in Auckland attended by Pacific Edge and NZX people, investors, analysts and the media, the company celebrated its growth, ... More >>
Pacific Edge Reports Continued Strong Revenue Growth Despite Ongoing Impact Of Covid-19
Thursday, 25 November 2021, 8:59 am | Pacific Edge
Cancer diagnostics business, Pacific Edge Limited (NZX/ASX: PEB) has reported continuing growth for the six months ended 30 September 2021 (1H22), with key performance metrics significantly ahead of the same time last year, driven by reimbursement milestones, ... More >>
Pacific Edge Announces Appointment Of New CEO
Friday, 29 October 2021, 9:37 am | Pacific Edge
Cancer diagnostics company Pacific Edge (NZX: PEB, ASX: PEB) today announces the appointment of Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer. Dr Meintjes, a New Zealand citizen ... More >>
Pacific Edge Financial Results For The 12 Months To 31 March 2021
Thursday, 27 May 2021, 9:32 am | Pacific Edge
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to report accelerating revenue growth in its key markets as it starts to benefit from the major commercial milestones achieved in FY21 and despite the ongoing challenges and headwinds ... More >>
Pacific Edge CEO, David Darling, Announces Intention To Retire
Monday, 12 April 2021, 9:59 am | Pacific Edge
Pacific Edge Limited (NZX: PEB) announces that CEO, David Darling, has advised the company’s Board that he intends to retire from his role on 6 April 2022. Following this, David will continue to support the company in a consulting role. The Board ... More >>
Commercial Evaluation Confirms Clinical Outperformance Of Cxbladder
Monday, 21 December 2020, 10:09 am | Pacific Edge
Peer reviewed publication of further independent, real-world clinical evidence highlights the effectiveness, safety and long term clinical utility from inclusion of Cxbladder in a new standard of care in mainstream clinical use. Cancer diagnostics company, ... More >>
Pacific Edge Appoints David Levison To USA Executive Team To Drive USA Growth
Thursday, 19 November 2020, 10:15 am | Pacific Edge
New Zealand cancer diagnostics company Pacific Edge Limited (NZX: PEB) today announces a new leadership structure to strengthen the executive team of its US based subsidiary, Pacific Edge Diagnostics USA Limited (PEDUSA). Coupled with this Pacific Edge is ... More >>
Pacific Edge Deemed An Essential Provider
Wednesday, 25 March 2020, 11:21 am | Pacific Edge
Cancer diagnostic company, Pacific Edge, advises that its medical and diagnostic services laboratories in both New Zealand and the USA have been identified as Essential Businesses and that they are operating during the Government-directed COVID-19 shutdowns. ... More >>
Significant achievement with Cxbladder added to guidelines
Monday, 15 July 2019, 2:21 pm | Pacific Edge
Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer in the USA. More >>
Pacific Edge Reports Continued Growth in FY19
Wednesday, 29 May 2019, 9:53 am | Pacific Edge
Cancer diagnostics company, Pacific Edge (NZX: PEB) has today released its audited financial results for the year ended 31 March 2019, reporting accelerating demand from new and existing customers in the second half of the financial year, particularly ... More >>
Further Compelling Clinical Evidence Supporting Cxbladder
Friday, 17 May 2019, 2:27 pm | Pacific Edge
• Cxbladder providing enhanced diagnostic outcomes not currently available from existing technology. • Enables physicians to remove the diagnostic dilemma faced, when existing gold standard tests and procedures are not able to determine a clear ... More >>
Full Suite of Cxbladder Tests Adopted by DHB
Thursday, 8 November 2018, 1:32 pm | Pacific Edge
Full Suite of Cxbladder Tests Adopted by New Zealand Public Healthcare Provider Capital & Coast Dhb Pacific Edge signs agreement with Capital & Coast District Health Board, providing access to full suite of Cxbladder products Cancer diagnostics company, ... More >>
Pacific Edge preliminary financial results for FY18
Tuesday, 29 May 2018, 1:20 pm | Pacific Edge
Listed cancer diagnostics company, Pacific Edge Limited (NZX: PEB), has today announced its preliminary unaudited full year results for the year ended 31 March 2018, reporting increased test numbers and revenues as more urologists and healthcare organisations ... More >>
Pacific Edge Signs First Commercial Agreement in Singapore
Thursday, 1 February 2018, 1:50 pm | Pacific Edge
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. More >>
